Interferon (IFN)-γ, tumor necrosis factor-α, interleukin-6, and IFN-γ receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis

Journal of Infectious Diseases

Volumn 194, Issue 7, 2006, Pages 958-965

  Ansari, Nasim A ^a   Ramesh, Venkatesh ^b   Salotra, Poonam ^a  

^a SAFDARJUNG HOSPITAL CAMPUS   (India)

^b SAFDARJUNG HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR 1; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INDIA; LEISHMANIASIS; MALE; PATHOGENESIS; POSTKALA AZAR DERMAL LEISHMANIASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN LEISHMANIASIS;

ADOLESCENT; ADULT; AGED; ANIMALS; CHILD; CYTOKINES; DOWN-REGULATION; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-6; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; RECEPTORS, INTERFERON; RNA, MESSENGER; SKIN DISEASES, PARASITIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748996809     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/506624     Document Type: Article

References (50)

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27:305-18.
2. Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002; 2:494-501.
3. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6:849-54.
4. Zijlstra EE, Musa AM, Khalil EAG, El-Hassan IM, El-Hassan AM. Post-kala azar dermal leishmaniasis. Lancet Infect Dis 2003; 3:87-98.
5. El Hassan AM, Khalil EA, El Sheikh EA, Zijlstra EE, Osman A, Ibrahim ME. Post kala-azar ocular leishmaniasis. Trans R Soc Trop Med Hyg 1998; 92:77-9.
6. Leng YJ. A review of kala-azar in China from 1949 to 1959. Trans R Soc Trop Med Hyg 1982; 76:531-7.
7. Noyes H, Chance M, Ponce C, Ponce E, Maingon R. Leishmania chagasi: genotypically similar parasites from Honduras cause both visceral and cutaneous leishmaniasis in humans. Exp Parasitol 1997; 85:264-73.
8. Ramesh V, Misra RS, Saxena U, Mukherjee A. Post kala-azar dermal leishmaniasis: a clinical and therapeutical study. Int J Derm 1993; 32:272-5.
9. El Hassan AM, Ghalib HW, Zijlstra EE, et al. Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment. Trans R Soc Trop Med Hyg 1992; 86:245-8.
10. Kemp K, Kemp M, Kharazmi A, et al. Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin Exp Immunol 1999; 116:500-4.
11. Kharazmi A, Kemp K, Ismail A, et al. T-cell response in human leishmaniasis. Immunol Lett 1999; 65:105-8.
12. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol 2005; 6:353-60.
13. Ansari NA, Saluja S, Salotra P. Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar. Clin Immunol 2006; 119:339-45.
14. Kenney RT, Sacks DL, Gam AA, Murray HW, Sundar S. Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis 1998; 177:815-8.
15. Singh R, Kumar D, Ramesh V, Negi NS, Singh S, Salotra P. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. I Infect Dis 2006; 194:302-6.
16. Thakur CP, Kumar K. Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programs. Ann Trop Med Parasitol 1992; 86:355-9.
17. Gasim S, Elhassan AM, Khalil EA, et al. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin Exp Immunol 1998; 111:64-9.
18. Ismail A, El Hassan AM, Kemp K, et al. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J Pathol 1999; 189:615-22.
19. Salotra P, Sreenivas G, Pogue GP, et al. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis. J Clin Microbiol 2001; 39:849-54.
20. Jeong CW, Ahn KS, Rho NK, et al. Differential in vivo cytokine mRNA expression in lesional skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT-PCR. Clin Exp Allergy 2003; 33:1717-24.
21. Karp CL, el-Safi SH, Wynn TA, et al. In vivo cytokine profiles in patients with kala-azar: marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest 1993; 91:1644-8.
22. Allione A, Bernabei P, Bosticardo M, Ariotti S, Forni G, Novelli F. Nitric oxide suppresses human T lymphocyte proliferation through IFN-gamma-dependent and IFN-gamma-independent induction of apoptosis. J Immunol 1999; 163:4182-91.
23. Stager S, Alexander J, Carter KC, Brombacher F, Kaye PM. Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect Immun 2003; 71:4804-7.
24. Xing Z, Wang J. Consideration of cytokines as therapeutics agents or targets. Curr Pharm Des 2000; 6:599-611.
25. Ghalib HW, Piuvezam MR, Skeiky YAW, et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993; 92:324-9.
26. Liew FY, Li Y, Millott S. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 1990; 145:4306-10.
27. Louzir H, Melby PC, Salah AB, et al. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J Infect Dis 1998; 177:1687-95.
28. Melby PC, Andrade-Narvaez FJ, Darnell BJ, Valenda-Pacheco G, Tryon VV, Palomo-Cetina A. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun 1994; 62:837-42.
29. Murray HW, Montelibano C, Peterson R, Sypek JP. Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J Infect Dis 2000; 182:1497-502.
30. Salotra P, Raina A, Ramesh V. Western blot analysis of humoral immune response to Leishmania donovani antigens in patients with post-kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 1999; 93:98-101.
31. May J, Lell B, Luty AJ, Meyer CG, Kremsner PG. Plasma interleukin-10: tumor necrosis factor (TNF)-alfa ratio is associated with TNF promoter variants and predicts malarial complications. J Infect Dis 2000; 182:1570-3.
32. Karplus TM, Jeronimo SM, Chang H, et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun 2002; 70:6919-25.
33. Ho AS, Liu Y, Khan TA, Hsu DH, Bazan JF, Moore KW. A receptor for interleukin 10 is related to interferon receptors. Proc Natl Acad Sci USA 1993; 90:11267-71.
34. Liu Y, Wei SH, Ho AS, de Waal Malefyt R, Moore KW. Expression cloning and characterization of a human IL-10 receptor. J Immunol 1994; 152:1821-9.
35. Dasgupta B, Roychoudhury K, Ganguly S, et al. Antileishmanial drugs cause up-regulation of interferon gamma receptor 1, not only in the monocytes of visceral leishmaniasis cases but also in cultured THP1 cells. Ann Trop Med Parasitol 2003; 97:245-57.
36. Ray M, Gam AA, Boykins RA, Kenney RT. Inhibition of interferon-gamma signaling by Leishmania donovani. J Infect Dis 2000; 181:1121-8.
37. Mohamed HS, Ibrahim ME, Miller EN, et al. Genetic susceptibility to visceral leishmaniasis in the Sudan: linkage and association with IL4 and IFNGR1. Genes Immun 2003; 4:351-5.
38. Blackwell JM, Mohamed HS, Ibrahim ME. Genetics and visceral leishmaniasis in the Sudan: seeking a link. Trends Parasitol 2004; 20:268-74.
39. Swihart K, Fruth U, Messmer N, et al. Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response. J Exp Med 1995; 181:961-71.
40. Tsuji M, Miyahira Y, Nussenzweig RS, Aguet M, Reichel M, Zavala F. Development of antimalaria immunity in mice lacking IFN-gamma receptor. J Immunol 1995; 154:5338-44.
41. Cillari E, Vitale G, Arcoleo F, et al. In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine 1995; 7:740-5.
42. Barral-Netto M, Barral A, Brownell CE, et al. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 1992; 257:545-8.
43. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001; 2:816-22.
44. Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 2001; 193:F5-9.
45. Tabbara KS, Peters NC, Afrin F, et al. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection. Infect Immun 2005; 73:4714-22.
46. Belkaid Y, Hoffmann KF, Mendez S, et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001; 194:1497-506.
47. Murray HW, Lu CM, Mauze S, et al. Interleukin 10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 2002; 70:6284-93.
48. Hatzigeorgiou DE, He S, Sobel I, Grabstein KH, Hafner A, Ho JL. IL-6 down-modulates the cytokine-enhanced antileishmanial activity in human macrophages. J Immunol 1993; 151:3682-92.
49. Teagu TK, Schaefer BC, Hildeman D, et al. Activation-induced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signalling. J Exp Med 2000; 191:915-26.
50. Sanceau J, Merlin G, Wietzerbin J. Tumor necrosis factor alpha and IL-6 upregulate IFN-gamma receptor gene expression in human monocytic THP-1 cells by transcriptional and post-transcriptional mechanism. J Immunol 1992; 149:1671-5.